MD Anderson at Cooper First in the World to Enroll a Patient In a Promising New Clinical Trial for Treatment of Metastatic Melanoma
December 08, 2023
December 08, 2023
CAMDEN, New Jersey, Dec. 8 -- Cooper University Health Care issued the following news release:
Researchers at MD Anderson Cancer Center at Cooper are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte (TIL) therapy. Earlier this year, MD Anderson at Cooper became the first site in the world to offer and enroll a patient in TILVANCE-301, a new randomized Phase III clinical trial evaluating the efficacy of TIL therapy as a first line tr . . .
Researchers at MD Anderson Cancer Center at Cooper are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte (TIL) therapy. Earlier this year, MD Anderson at Cooper became the first site in the world to offer and enroll a patient in TILVANCE-301, a new randomized Phase III clinical trial evaluating the efficacy of TIL therapy as a first line tr . . .